SCHEMBL6980552

SCHEMBL6980552

O=C(CO)NCO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methoxymethane SCHEMBL9700240 0.88 RECQL (0.39)
Ether SCHEMBL9560126 0.82 GAA (0.35)
SCHEMBL3305420 0.81 ALDH1A1 (0.41)
SCHEMBL8995940 0.79 ALDH1A1 (0.44)
SCHEMBL1156656 0.79 ALDH1A1 (0.41)
SCHEMBL9559963 0.78 EPHX2 (0.36)
SCHEMBL3051875 0.78
SCHEMBL6980549 0.76
SCHEMBL27628786 0.76 ALDH1A1 (0.31)
SCHEMBL3685052 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200324027-A1 IMMOBILISED BIOLOGICAL ENTITIES GORE & ASS (US) 2020-10-15 US disclosed
EP-1534291-B1 2-(PHENYLTHIOMETHYL)- MORPHOLINE DERIVATIVES FOR USE AS SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS LILLY CO ELI (US) 2008-11-12 EP disclosed
EP-0985671-B1 PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARM CO LTD (JP) 2003-04-02 EP disclosed
US-6476021-B1 Compounds having cGMP-PDE inhibitory effect MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-11-05 US disclosed
US-6197768-B1 THERAPY, PREVENTION ISCHEMIC HEART DISEASE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2001-03-06 US disclosed
EP-1048666-A1 NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-11-02 EP disclosed
EP-0992240-A1 THERAPEUTIC AGENT FOR ERECTION FAILURE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-04-12 EP disclosed
EP-0985671-A1 PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-03-15 EP disclosed
US-6018046-A SELECTIVE ACTION IN INHIBITING CYCLIC GMP-PHOSPHODIESTERASE (CGMP-PDE); PHARMACEUTICALS FOR TREATING DISEASES AGAINST WHICH THE INHIBITORY ACTION IS EFFECTIVE, SUCH AS PULMONARY HYPERTENSION MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-01-25 US disclosed
EP-0340254-A1 PACKAGE AND WRAPPER Daniel, Peter Gottfried (DE) 1989-11-08 EP disclosed
EP-0311571-A1 Packaging and packet SANDOZ AG (CH) 1989-04-12 EP disclosed
US-4587246-A CARDIOTONIC IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1986-05-06 US disclosed
US-4503054-A VASODILATORS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1985-03-05 US disclosed
EP-0002518-B1 CONDENSATION PRODUCT OF EPSILON-CAPROLACTAM, FORMALDEHYDE AND FORMAMIDE, AMINOPLAST MODIFIED BY THIS CONDENSATION PRODUCT AND PROCESS FOR THE PREPARATION OF THE AMINOPLAST CASSELLA Aktiengesellschaft (DE) 1981-11-04 EP disclosed
EP-0002518-A2 Condensation product of epsilon-caprolactam, formaldehyde and formamide, aminoplast modified by this condensation product and process for the preparation of the aminoplast CASSELLA Aktiengesellschaft (DE) 1979-06-27 EP disclosed